Workflow from Scientific Research

An overview of the study design is shown. All patients could opt to receive the study drug postoperatively. After surgery, patients in the untreated control group were re-randomized 1:1 to either vorasidenib 50 mg q.d. or ivosidenib 500 mg q.d. Based on the PD and pharmacokinetic results of cohort 1, alternative dose regimens of vorasidenib and/or ivosidenib were to be tested in cohort 2.

DOI